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CASE REPORT
[3120+1kbdel8.6kb]+[p.N1303K] GENOTYPE IN AN EMIRATI CYSTIC
FIBROSIS PATIENT: INDICATION OF A FOUNDER MUTATION IN
PALESTINIAN ARABS
Danish Saleheen, Philippe M. Frossard, Emmanuelle Girodon
Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan and *Laboratoire de Genetique Moleculaire,
INSERM U91, Hospital Henri Mondor, Creteil, France.

Cystic fibrosis (CF) is the most common life-limiting autosomal recessive disorder in Caucasian
population. The disease was initially considered to be rare in Middle Eastern countries. 95% of CF
in Emirati families is due to two mutations only – p.S549R(T>G) and p.F508del. We report here
the case of a patient referred to CF and Respiratory Clinic at Tawam Hospital for cystic fibrosis
transmembrane regulator (CFTR) gene screening to ascertain the diagnosis of CF, who was found
to carry a unique genotype, signifying the importance of retrieving ancestral histories of patients
with monogenic disorders
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INTRODUCTION
Cystic fibrosis (CF) is the most common life-limiting
autosomal recessive disorder in
Caucasian
population.1 It is a multisystem disorder characterized
by a constellation of symptoms mainly including
chronic bacterial infection of airways, pancreatic
insufficiency, infertility in males and increased
concentration of chloride in sweat.1 It is caused by
defect in a 190 kb gene on chromosome 7 encoding a
1480 amino acid polypeptide, named cystic fibrosis
transme mbrane regulator (CFTR).1,2 To date 1523
CFTR gene mutations have been identified,
responsible for CF or related diseases .3
Cystic fibrosis occurs in an estimated 1 in
2500 live births in Caucasians.1 However its
incidence is quite variable, and ranges fro m 1/500 in
Ohio Amish to 1/90000 in Hawaiian Orientals .1 The
disease was initially considered to be rare in Middle
Eastern countries.4 However better awareness and
improved diagnostic tools have suggested a higher
incidence.5 Since the startup of the first Cystic
Fibrosis and Respiratory Clinic at Tawam hospital,
Al Ain, U.A.E. in 1995, there has been an increased
awareness on cystic fibrosis among general
practitioners and pediatricians in the region.6 In a
study aimed at identifying the mutations responsible
for the disease in the Emirati population, it was found
that the pattern of CF-causing mutations is different
in this population as compared to the other Arab
populations in the region.5-6 Indeed, 95% of CF in
Emirati families is due to two mutations only –
p.S549R(T>G) and p.F508del.5 We report here the
case of a patient referred to CF and Respiratory
Clinic at Tawam Hospital for CFTR gene screening
to ascertain the diagnosis of CF, who was found to
carry a particular genotype.

CASE REPORT
The proband is a boy who was referred at 2 months
of age. He was born to a non-consanguineous healthy
couple by normal vaginal delivery. Birth weight was
3.85 kg. He was first referred with respiratory
distress and poor feeding. During the workup of the
infant in the ward, his respiratory tract showed
colonization
of
micro-organisms
including
Stenotrophomonas maltophilia and Pseudomonas
aeruginosa. His condition deteriorated and he was
transferred to intensive care unit for assisted
respiration for five days. Abdominal X-rays showed
wide spread calcifications suggestive of meconium
peritonitis. The patient was administered intravenous
antibiotic therapy and his condition gradually
improved. Sweat chloride concentration was
100mmol/L. He was also found to be pancreatic
insufficient based on the presence of steatorrhea and
measurement of stool chymotrypsin activity which
was done as described previously.7 Presence of
Pseudomonas aeruginosa in the respiratory tract,
meconium peritonitis, high sweat chloride values and
pancreatic insufficiency, all point towards cystic
fibrosis and thus a genetic confirmation was done by
CFTR gene analysis.
CFTR gene analysis
The protocol for CFTR gene screening was approved
by the Research Ethics Committee of the Faculty of
Medicine and Health Sciences, UAE University, Al
Ain, UAE. A blood sample was collected and DNA
was extracted from leukocytes using a reference
phenol-chloroform protocol. The two most common
mutations (p.S549R(T>G) and p.F508del) were
initially screened as described previously,5 but were
not found. Thirty-one most frequent mutations were
further screened using the CF assay (Abbot, Rungis,
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France): the p.N1303K mutation was found on one
allele. The search for a second mutation was then
initiated using denaturing gradient gel electrophoresis
(DGGE) focused on the 27 coding regions8-9 : no
additional mutation could be identified. One of the
parents forefathers being from Palestine, we further
screened for a large deletion removing exons 17a to
18, 3120+1kbdel8.6kb, which has been found
frequent in Palestinian Arab CF patients and
proposed as a founder mutation amongst Palestinian
Arabs.10-11 The boy was heterozygous for this
deletion,
thus
carrying
the
[3120+1kbdel8.6kb]+[p.N1303K] genotype.

DISCUSSION
So far, it has been observed that mutations p.F508del
and p.S549R(T>G) account for 88% of chromosomes
in UAE and explain 95% of CF in Emirati families,
almost all the reported CF patients being
homozygous for either of the two mutations.5
Moreover, the clinical phenotypes associated with
both mutations were homogeneous and extremely
severe, including dramatic losses of pulmonary
function.
The patient described harboring the large
3120+1kbdel8.6kb deletion in the CFTR gene is
unique and further documents the hypothesis of a
founding effect of this mutation in Palestinian Arabs.
3120+1kbdel8.6kb was first identified by Lerer et
al.10 in four Palestinian patients. The mutation causes
a deletion of exons 17a, 17b and 18. This is one of
the few large deletions that have been described in
the CFTR gene.3 This mutation causes an in-frame
deletion of 160 amino acids that are part of
transmembrane domains 10-12 of the CFTR
protein.10 This mutation was later found to have a
13% prevalence in Palestinian Arabs.11 Patients with
both a homozygous state and a compound
heterozygous state for this mutation have been
reported with a severe phenotype.10-11 The intragenic
haplotype and the flanking markers were identical in
all the chromosomes bearing the deletion in the four
Arabs reported, indicating ht at this mutation si an
ancient founder mutation.10 The linked haplotype
could not be determined in our case, as the parents
were not available.
The other mutation found in this patient,
p.N1303K, was first described by Osborne et al. in
1991.12 Genotype-phenotype correlations clearly
indicate that this mutation is severe with respect to
pancreas status but conclusions on its effect on lung
disease vary among studies.13-14 The frequency of
this mutation is variable among populations. It was
indeed identified in homozygosity in eight
Palestinian Arab CF patients, and accounted for 21%
CF alleles in this population.10
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The fact that the compound CFTR genotype
[3120+1kbdel8.6kb]+[p.N1303K] is observed in this
patient of Palestinian ancestry, together with the
consideration that the deletion has only been
described in Palestinian Arabs so far, further
documents the hypothesis that 3120+1kbdel8.6kb is a
founder mutation in Palestinian Arabs. This case
report also emphasizes the importance of retrieving
ancestral histories of patients with monogenic
disorders, and especially in the case of CF, a disease
in which patterns of CFTR mutations vary greatly
among populations.
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